RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology
The post RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- M-A | Catheter-directed thrombolysis vs. systemic thrombolysis and anticoagulation in intermediate- or high-risk pulmonary embolism
- AHA Scientific Statement | Pulmonary hypertension in congenital heart disease
- RCT | Cytisinicline shows significant efficacy in smoking cessation over placebo
- M-A | Adjunctive corticosteroids improve survival, clinical outcomes in severe community-acquired pneumonia
- M-A | Drug therapies for treatment of idiopathic pulmonary fibrosis